Cliff Asness's APLS Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 2.28 M shares of Apellis Pharmaceuticals, Inc. (APLS) worth $57.19 M, representing 0.03% of the portfolio. First purchased in 2019-Q4, this long-term strategic position has been held for 23 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in APLS, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2025, adding 2.22 M shares. Largest reduction occurred in Q4 2025, reducing 2.21 M shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Apellis Pharmaceuticals (APLS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Apellis Pharmaceuticals (APLS) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -2.21 M | Reduce 49.26% | 2.28 M | $25.12 |
| Q3 2025 | -1.49 M | Reduce 24.92% | 4.49 M | $22.63 |
| Q2 2025 | +1.9 M | Add 46.57% | 5.98 M | $17.31 |
| Q1 2025 | +2.22 M | Add 119.64% | 4.08 M | $21.87 |
| Q4 2024 | +1.04 M | Add 127.15% | 1.86 M | $31.91 |
| Q3 2024 | +570,380 | Add 231.04% | 817,260 | $28.84 |
| Q2 2024 | +190,420 | Add 337.27% | 246,880 | $37.17 |
| Q1 2024 | +56,460 | New Buy | 56,460 | $57.70 |
| Q3 2023 | -10,926 | Sold Out | 0 | $0.00 |
| Q2 2023 | -4,263 | Reduce 28.07% | 10,926 | $91.10 |
| Q1 2023 | -2,002 | Reduce 11.65% | 15,189 | $65.96 |
| Q4 2022 | +8,792 | Add 104.68% | 17,191 | $51.71 |
| Q3 2022 | +92 | Add 1.11% | 8,399 | $68.34 |
| Q2 2022 | +8,307 | New Buy | 8,307 | $45.26 |
| Q4 2021 | -40,966 | Sold Out | 0 | $0.00 |
| Q3 2021 | +36,478 | Add 812.79% | 40,966 | $32.95 |
| Q2 2021 | +4,488 | New Buy | 4,488 | $63.28 |
| Q1 2021 | -3,941 | Sold Out | 0 | $0.00 |
| Q4 2020 | -11,928 | Reduce 75.17% | 3,941 | $57.09 |
| Q3 2020 | -11,044 | Reduce 41.04% | 15,869 | $30.18 |
| Q2 2020 | -7,298 | Reduce 21.33% | 26,913 | $32.66 |
| Q1 2020 | +13,591 | Add 65.91% | 34,211 | $26.80 |
| Q4 2019 | +20,620 | New Buy | 20,620 | $30.60 |
Cliff Asness's Apellis Pharmaceuticals Investment FAQs
Cliff Asness first purchased Apellis Pharmaceuticals, Inc. (APLS) in Q4 2019, acquiring 20,620 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Apellis Pharmaceuticals, Inc. (APLS) for 23 quarters since Q4 2019.
Cliff Asness's largest addition to Apellis Pharmaceuticals, Inc. (APLS) was in Q1 2025, adding 4,077,419 shares worth $89.17 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 2,276,687 shares of Apellis Pharmaceuticals, Inc. (APLS), valued at approximately $57.19 M.
As of the Q4 2025 filing, Apellis Pharmaceuticals, Inc. (APLS) represents approximately 0.03% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Apellis Pharmaceuticals, Inc. (APLS) was 5,976,414 shares, as reported at the end of Q2 2025.